Asahi Kasei to Acquire Aicuris Anti-infective Cures AG

Asahi Kasei entered into a definitive agreement to acquire Aicuris Anti-infective Cures AG, a German biopharmaceutical company, for approximately €780 million. The acquisition is designed to expand Asahi Kasei’s specialty pharmaceutical platform into severe infectious diseases and to complement its existing transplant and nephrology franchises. A second article reports Asahi Kasei completed the acquisition.